Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.
We report 1 patient with a necrolytic migratory erythema, a high plasma glucagon concentration and a metastatic pancreatic endocrine tumor who has now been treated effectively for 33 months with the somatostatin analogue octreotide (SMS 201-995) (400 micrograms/day). The results of SMS 201-995 in the treatment of glucagonoma syndrome are reviewed.
Rosenbaum
A
A
Service de Gastroentérologie, Hôpital Saint-Lazare, Paris, France.
Flourie
B
B
Chagnon
S
S
Blery
M
M
Modigliani
R
R
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000368:Aged; D005260:Female; D005935:Glucagonoma / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D013577:Syndrome
D015282:Octreotide